Skip to main content

Advertisement

Fig. 1 | Cancer Communications

Fig. 1

From: Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Fig. 1

Waterfall plot of the change of maximal tumor diameter at 12 weeks after neoadjuvant therapy initiation. Each bar represents the datum of 1 individual patient. Negative values represent diameter reduction, and positive values represent diameter increment. A change greater than − 30% indicates partial response, − 30% to 20% indicates stable disease, and greater than 20% indicates progressive disease

Back to article page